

April 26, 2010

Dear BioRx Vivaglobin® Patient:

As many of you have heard, CSL Behring has released a new product called Hizentra™ (20% subcutaneous immune globulin). While there is no date set, it is anticipated that Hizentra will replace Vivaglobin (16% subcutaneous immune globulin) sometime in the next 12 to 18 month timeframe. We at BioRx want to keep you and your physician informed of how this process will be carried out.

To facilitate a smooth transition, and ensure no interruption of service or any surprises in coverage or financial obligations, we are working continually up-front and behind the scenes in the following areas:

- Distributing patient education material on Hizentra as it becomes available
- Training and education of BioRx Advocacy, Pharmacy and Nursing staff
- Commercial and Government payer awareness and formulary information
- Pre-Verification of insurance coverage for Hizentra
- Obtaining new prescriptions from physicians

Considering any changes in your therapy should be thoroughly discussed with your physician. For your convenience included below are some important facts about Hizentra:

- Storage is at room temperature, not requiring refrigeration
- May infuse up to 25ml/site resulting in less infusion time
- Fewer infusion sites possible due to increased concentration and increased volume per site
- Very low IgA content (≤50 mcg/ml)
- Stabilized in proline (no sugars)

Hizentra dosing will be decided between you and your doctor, but we believe it will likely remain the same as your current dose of Vivaglobin. Beginning immediately, and throughout the transition period, we will contact your physician to explain this process and, if appropriate, obtain new orders for Hizentra at that time. Of course BioRx will maintain an inventory of Vivaglobin as long as it is available and will continue to provide you with your current supplies as long as necessary. Additionally, we will make sure all authorizations from your insurance company are in place prior to dispensing Hizentra.

If you have any questions about Hizentra or the transition process, please contact your advocate, myself, our pharmacy staff or your physician. For additional product information, visit www.hizentra.com. Thank you for choosing BioRx for your infusion needs. We enjoy taking care of you and look forward to providing for you in the future.

Sincerely,

Carol Ernst

Carol Ernst, RN
Director Consumer Advocacy PIDD
BioRx
800-559-3173 Toll Free
cernst@biorx.net